Skip to main content
. 2022 Feb 23;4:100073. doi: 10.1016/j.conx.2022.100073

Fig. 3.

Fig. 3

Cumulative distribution of the MPA concentration when ovulation returns (progesterone ≥ 4.7 ng/mL) following subcutaneous administration of 45–300 mg Depo-Provera or 104 mg Depo-subQ in two trials conducted between 2015 and 2018 [10,11]. Dashed lines and 95% confidence bands are based on non-parametric maximum likelihood estimation. Solid curve is Weibull model fit, which was used to estimate covariate effects in Table 2. Abbreviation: MPA, medroxyprogesterone acetate.